Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 2
5(62.5%)
Phase 1
3(37.5%)
8Total
Phase 2(5)
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07552181Phase 2Not Yet Recruiting

Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product, MO-03, in Patients With Early Stage Triple Negative Breast Cancer

Role: collaborator

NCT07181486Phase 1Recruiting

Safety Study of MucoCept-CVN

Role: collaborator

NCT05022212Phase 2Completed

Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition

Role: collaborator

NCT06399419Phase 1Recruiting

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Role: lead

NCT00305227Phase 2Completed

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Role: collaborator

NCT00537576Phase 1Completed

Safety Study of Lactobacillus Administered Vaginally to Healthy Women

Role: lead

NCT01077245Phase 2Withdrawn

Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections

Role: lead

NCT00635622Phase 2Completed

Safety and Efficacy Study of Lactobacillus Administered Vaginally in Women With Bacterial Vaginosis

Role: lead

All 8 trials loaded